Exondys 51

Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Flag link:
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Endpoints
Sarepta Therapeutics
patients
patents
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Stat
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
golodirsen
Exondys 51
Flag link:
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
BioPharma Dive
Anthem
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
3 Biotech Stocks That Could Soar in September
3 Biotech Stocks That Could Soar in September
Motley Fool
biotech
fitusiran
Alnylam
PTC Therapeutics
Translarna
Sarepta
Exondys 51
Flag link:
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
Payor Re-Evaluation On Exondys Positive For Sarepta
Payor Re-Evaluation On Exondys Positive For Sarepta
Yahoo/Benzinga
payers
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
Sarepta May Have More Upside After Sales Data
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta eyes a different approach to Duchenne: gene therapy
Sarepta eyes a different approach to Duchenne: gene therapy
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
gene therapy
Flag link:
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Will Insurers Pay For Sarepta’s DMD Drug?
Will Insurers Pay For Sarepta’s DMD Drug?
Barron's
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
Medicaid
payers
insurers
Flag link:
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
Endpoints
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
FDA official warns other drug makers not to copy Sarepta
FDA official warns other drug makers not to copy Sarepta
Stat/Pharmalot
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
Major US insurer snubs Sarepta's Duchenne drug
Major US insurer snubs Sarepta's Duchenne drug
BioPharma Dive
Anthem
insurerrs
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link: